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In recent Coimbra’ Conference, on the pre-launch of pathogen reduced-FFP for the local
clinical use, the question was raised, by the moderator, on the eﬃcacy of the current
methodology used for prion removal processes and its inﬂuence on the overall quality
and safety of the ﬁnal product. This brief paper put together by speaker of this session
and the moderator, as a consensus of opinions, which was largely discussed during Q&A
session, to make it available to a large group of readers of transfusion apheresis science,
who might be interested to this topic. In short the capacity of the current process of
Octaplas to remove prion is in order of 5.6 log10/ID50 reduction based on several animal
studies. Moreover the changes in coagulation and inhibitors are within acceptable range
and bioequivalent to untreated FFP with no sign of inferiority. This paper describes in
brief a technology update on solvent/detergent treated plasma, an alternative to FFP but
with increased pathogen safety. The biochemical proﬁle of the ﬁnal product is compara-
ble with FFP and contains all clinically relevant plasma proteins. Furthermore, Octaplas is
a product that, in long term, reduces health care costs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Plasma-derivativesareessential therapeuticmodalities,used
to control bleedings and treat immunological disorders. Being
ofhumanorigin,asstartingmaterial, theseproductsarebearing
at least a theoretical risk of causing transfusion transmitted
infection [TTI], inparticular in casesof plasmadonationduring
the window period. TTI still occurs occasionally, despite NAT
testing, and fears of emerging/re-emerging viruses still exist
and of course prions, where no testing procedure for its iden-
tiﬁcation, yet available. Therefore, in addition to providing a
normal coagulation protein proﬁle and coagulant capacity,
pathogen inactivation/reductioncombinedwithprionremoval
process plays an equal important role in optimizing the clin-
icalneedof patients,withhighestdegreeof safetymargin [1,2].
Although the plasma used for the production of Octaplas
is NAT tested (HIV, ParvoB19, HAV, HBV, HCV, HEV), two steps
are part of themanufacturing process to inactivate/neutralize
viruses: solvent/detergent treatment for the inactivation of
enveloped viruses and immune neutralization of both non-
enveloped and enveloped viruses. However, these steps do not
contribute to the risk reduction for prion transmission, for
either free or cell-bound forms, the potential infectious agent,
which leads to the development of transmissible spongiform
encephalopathy such as the Creutzfeldt–Jakob disease (CJD),
especially its variant form (vCJD). CJD was ﬁrst transmitted
iatrogenically in 1972 (corneal transplant), four cases have
developed vCJD after receiving transfusion of non-leukocyte
reduced red cells [3] and a hemophilia patient developed vCJD
where a factor VIII concentrate was the most likely route of
infection [4] The former is of particular relevance as the
implementation of pre-storage universal leukodepletion [ULD]
process, as precautionary measure to be rather “safe than
sorry”, does not appear to be fully effective in eradication of
prion proteins in plasma. Moreover, ULD of blood and its
cellular components does not retain or generate further
micro-vesicles/cell fragments and prions [5].
2. The state of the art of the SD-FFP in respect to
implementation of prion removal ﬁlter
As prions by deﬁnition are proteins, inactivation is not
possible inmedicinal products, comprising sensitive plasma
proteins. Thus, a prion removal step has to be part of each
plasma-derivative manufacturing process. This require-
ment is valid since 2004 and is part of the CPMP guidelines
[6]. Multiple experimental infectivity studies have demon-
strated that severalmanufacturing steps, inparticular ethanol
fractionation, depth ﬁltration, nanoﬁltration, and chroma-
tography can remove 3–5 logs of spiked prions, probably
by partitioning and size-exclusion/trappingmechanisms [7].
Such production steps are included in the manufacture of
plasma-derivatives such as albumin, immunoglobulins, and
factor concentrates, with success, but not in the preparation
of plasma used for transfusion – virus inactivated or not.
To investigate thepotential for prion removal of themanu-
facturingprocess forOctaplas(1stgenerationproduct),apooled,
S/Dtreatedplasmafor transfusion, a studywasperformedwith
chronicallyscrapie infectedmurineneuroblastomacells (ScN2a)
to see what the effect of complete cell removal on prion
infectivitywouldbe[8].Furthermore, thedown-streamOctaplas
manufacturingprocesswas investigatedfor itsprion(notbound
to cells) removal capacity [8]. Itwas demonstrated that a total
reduction factor (RF) of 2.5 log10 could be achieved over the
total Octaplas manufacturing process.
To further improve the safety margin of Octaplas in
terms of the theoretical risk for prion transmission,
a speciﬁc aﬃnity ligand chromatography step, which
binds prion proteins, has been implemented into the manu-
facturing process of the 2nd generation product, often
referred to as OctaplasLG. The prion binding capacity per
milliliter ligand gel was investigated using both interme-
diates and the ﬁnal Octaplas product spiked with 263K
hamster brain-derived prion (PrPSc)-containing fractions [9].
A validated Western blot (WB) test was used for the
identiﬁcation and quantiﬁcation of PrPSc. After the imple-
mentation of the prion removal chromatography step into
the Octaplas manufacturing process (2nd generation) a total
RF of ≥3.0 log10 was demonstrated [9]. Within this study it
was further shown that the resin has the ability to bind
infectious prion from sources like human vCJD and spo-
radic CJD. These WB results from the ﬁrst study were
conﬁrmed in a second study where a total RF of ≥3.1 log10
was achieved [10].
At the same time as the implementation of the aﬃnity
chromatography step the solvent/detergent treatment step
was amended. Thus, overall WB results from the old study
(1st generation product) cannot be compared with the
results obtained for the 2nd generation product.
A bioassay study was performed in addition and the
titration of these samples showed a RF of 2.99 log10
which is comparable with the WB total RF achieved after
the implementation of the aﬃnity ligand chromatography
step [10].
3. Product characteristic in terms of
hemostatic potency
Anymanufacturing step canhave an impact on thequality
of the active principles of plasma. Therefore, after the incor-
poration of a new step or after a step optimization it has to be
shown that the biochemical proﬁle as well as the eﬃcacy of
theﬁnal product has not been changed. Tomaximize the clin-
icalvalueofOctaplas theS/Dtreatmentstephasbeenoptimized
in parallel to the implementation of the prion removal chro-
matography step. To improve the concentration of S/D labile
plasma proteins such as plasmin inhibitor (PI, also known as
α2-anti-plasmin) and protein S (PS) bymaintaining the virus
safety, the timeof S/D treatment at 30 ± 1 °Chasbeen reduced
from4–4.5hours to1–1.5hours in the2ndgenerationproduct
(OctaplasLG). Validation studieshavebeendemonstrated that
the reduced S/D treatment time is still enough to inactivate
enveloped viruses within fewminutes below the limit of de-
tection [11]. Except a decrease of protein S and PI activity the
S/D treatment optimization has not changed the biochemical
proﬁle of the ﬁnal product [12]. The same is valid for the in-
corporation of the prion removal chromatography into the
Octaplas manufacturing process. It has been shown that the
implementationof thisstepdoesnotadverselyaffect theproven
hemostatic quality of Octaplas [13].
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4. Future trends
Octapharma has also developed Uniplas/UniplasLG, a
non-blood group speciﬁc, solvent detergent treated plasma.
Uniplas/UniplasLG differs from Octaplas/OctaplasLG only in
the way as an optimized integration and thoroughly deﬁned
pooling of plasma donations of different blood groups
facilitates the production of a blood group independent,
universally transfusable plasma. Uniplas/UniplasLG is not
licensed in the US, Canada or EU but is used with good
results in Ireland since 2002 on a named patient basis [12].
Octaplas as well as OctaplasLG are produced in two, au-
thority approved, manufacturing plants, Vienna, Austria and
Stockholm, Sweden.
Octaplas is licensed in Portugal since 1995 and in a recent
meeting, which took place between Instituto Português do
Sangue e da Transplantação (IPST) and Octapharma, the
manufacturing of Octaplas 2nd generation for Portugal on
a self-suﬃciency basis has been discussed. This concept has
been implemented very successfully in different European
countries.
5. Summary and conclusion
When a speciﬁc prion aﬃnity removal step is introduced,
it is also of great importance to investigate the prion binding
capacity of the resin or ﬁlter until saturation. Therefore, such
a study was incorporated into the bioassay study. A
reproducible prion infectivity binding capacity per milliliter
resin of 5.645 log10/ID50 and 5.650 log10/ID50was demonstrated,
providing a large safety margin [12].
As infectivity has recently been found in erythrocytes,
leukocytes, and plasma of a person with vCJD and in the
plasma in 2 out of 4 persons with spCJD [14], it is impor-
tant to continue a thorough CJD surveillance and tomaintain
and/or increase the safety of blood components and plasma-
derivatives. A therapeutic plasma with minimized risk of
pathogen transmission is of great importance, especially for
patients in regular receipt of large volumes of plasma, e.g.
individuals suffering from thrombotic thrombocytopenic
purpura (TTP) [15] which receives an average of 40 l of
plasma over the ﬁrst 7 days of treatment [16] and in fact
for all users of FFP.
OctaplasLG is used in different countries routinely since
several years and a recently performed clinical trial showed
that Octaplas as well as OctaplasLG compensate well for the
loss of clotting factors after apheresis [17].
OctaplasLG fulﬁlls the regulatory requirements of the
European Union, Canada as well as the USA.
Already performed cost effectiveness and budget impact
analysis studies of OctaplasLG compared to FFP have shown
thatOctaplasLG is thedominant treatmentoptionover FFP for
UK, Canada and the USA. Acute and long-term complications
of plasma transfusions were modeled in a decision tree fol-
lowed by aMarkovmodel. Over a life time horizon, the costs
withOctaplasLGwere less than thosewith FFP.OctaplasLG re-
sulted inslightlymorequalityadjusted lifeyears (QALYs)gained
in comparison with FFP [18–20]. Based on the long term ex-
perience and the existing data we believe that the current
process in place in the preparation of SD-FFP is an updated
technologywhich has a higher purity and safety than FFP and
contains optimal levels of the relevant active proteins re-
quired for theoptimalclinicaloutcomewithminimaluntoward
reactions, that in long term reduces health care costs.
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